Jazeta Novum

Sitagliptin, the active ingredient in Jazeta Novum, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used as part of a comprehensive diabetes treatment plan that includes diet and exercise.

GNH USA supplies Jazeta Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Jazeta Novum, a DPP‑4 inhibitor, is used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels as part of a diet‑and‑exercise regimen. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin or other oral antidiabetic agents. - Type 2 diabetes mellitus (adjunct to lifestyle): supports maintenance of target HbA1c when diet and exercise alone are insufficient.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Nausea: occasional stomach upset. - Diarrhea: loose stools that are usually self‑limiting. - Joint pain: arthralgia without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: elevated liver enzymes or jaundice. - Acute renal failure: sudden decrease in kidney function. - Cardiovascular events: rare reports of heart failure exacerbation.

Before initiating therapy, consider the following precautions: - Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: avoid or monitor closely for recurrence. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Cardiovascular disease: monitor patients with existing heart conditions. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with other medicines; review the following categories: Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase sitagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce sitagliptin exposure. Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Diuretics: may affect glycemic control. - ACE inhibitors or ARBs: monitor renal function and electrolytes.